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The creation of vaccines for many different illnesses has now allowed humans to live in a 
world where we are mostly burdened by non-communicable diseases due to lifestyle choices. 
Although some vaccines have almost completely eradicated some illnesses, the influenza virus 
continues to be a long lasting public health threat even though a vaccine has long since been 
created for this virus. The history of influenza epidemics and pandemics are well documented as 
these outbreaks can be traced back with some accuracy for the past three-hundred years (Potter, 
2008). With this historical knowledge we have seen the devastation this virus can cause in 
pandemics such as the Spanish Influenza outbreak of 1918 and even in outbreaks as recent as the 
Swine Flu outbreak of 2009. As a result, study of the influenza virus is naturally significant and 
important because this virus has the ability to cause high rates of illness and death in humans 
regardless of how developed our society has become. The risk the influenza virus poses to 
humans has caught the focus of many different fields of professionals including researchers, 
epidemiologists, physicians, and the pharmaceutical industry as these groups of people have 
generated a vast amount of literature and knowledge in regards to this topic (Potter, 2008). The 
influenza virus has withstood the test of time by continuing to be a major public health problem 
because this virus continues to have a major worldwide impact by causing serious illness, death, 
and economic burden as a result of recurrent influenza epidemics that can be attributed to the 
viral property of antigenic drift (Carrat & Flahault, 2007).Unlike bacteria or some other agents of 
illness, the influenza virus has the ability to change its genetic code via antigenic drift which has 
caused the emergence of many different strains of the virus. The implications of this ability are 
significant to public health because being able to create different strains, some of which are 
completely novel, means that humans can continuously be infected by the influenza virus even if 
they have gotten this virus before as there is always the possibility of being infected by a new 
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strain that the immune system does not recognize (Carrat & Flahault, 2007). Therefore there is a 
critical need for continuously changing vaccination policies and available vaccines to keep up 
with the evolution of the influenza virus, and there are institutions worldwide which were created 
solely for this purpose. Each country has the liberty to handle their influenza vaccination policies 
differently, but every vaccination program must have a measureable outcome. For the United 
States the Advisory Committee on Immunization regularly updates why vaccination against 
influenza is important, and most rationales argue that the influenza vaccine reduces factors like 
hospital visits, mortality rates, and economic burden (Jefferson, 2006). In the United States there 
seems to be a new trend where people are becoming distrustful of vaccination in general, but the 
need for vaccination is crucial as the seasonal influenza vaccine is really our only protection 
against this extremely dangerous virus. Therefore there is more pressure than ever to prove to 
society that that influenza vaccine is important to public health and effective so the majority of 
people will still be motivated to get their influenza vaccine each year. Encouraging the public to 
get vaccinated against the influenza virus is not always an easy task as the influenza vaccine has 
not always had the best reputation because some people think it is ineffective or will make them 
sick. Unfortunately there is some truth to these reservations because some years the influenza 
vaccine is not as effective as it was intended to be because there is not much human control over 
how and when the prevalent influenza strains will evolve. The purpose of this paper is to 
examine the efficacy of the influenza vaccine and its implication on vaccination policy as 
maintaining or increasing vaccination efficacy is important to public health intervention against 
this virus. To achieve this purpose a literature review will be conducted based on peer-reviewed 
research to examine current vaccination policy, efficacy of the influenza vaccine, approaches to 
improve efficacy, and the gap between vaccination policy and scientific evidence. 
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 International relations can sometimes be strained due to differences in ideology on many 
issues, but current influenza vaccination policy is very much dependent on a collective 
worldwide effort. All countries agree that the influenza virus is a danger to public health 
worldwide especially in an era where there is so much international travel which heightens the 
risk of quickly spreading illness like influenza. To get an idea of the scale of this worldwide 
effort, currently there are 142 national influenza centers in 113 different countries which conduct 
year-round surveillance for prevalent circulating influenza strains and disease trends (CDC, 
2015). This part of the policy gives insight into influenza evolution because in terms of the 
spread of the prevalent strains seasonally, each country cannot be treated as on isolated region 
because geography plays an important role worldwide in which strains are most relevant at any 
given time. With 142 contributing laboratories a vast amount of data is produced so in order to 
come to a conclusion on which of the many influenza strains should be included in the vaccine 
for each year the World Health Organization has five collaborating centers located in five 
different countries which include the United States, United Kingdom, Australia, Japan, and 
China (CDC, 2015). These five collaborating centers help narrow down the most prevalent 
strains for each season, and ultimately the World Health Organization makes a worldwide 
suggestion on which strains they feel should be included in each country’s seasonal influenza 
vaccine. In the United States each seasonal flu vaccine protects against three or four strains of 
the influenza virus based on the provided recommendations by the World Health Organization 
and therefore our seasonal influenza vaccine is referred to as trivalent or tetravalent. The most 
common circulating strains of influenza amongst humans today are Influenza A (H1N1), 
Influenza A (H3N2), and Influenza B therefore these strains or variations of these strains are 
usually included in the United States’ seasonal influenza vaccine (CDC, 2015). Although the 
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CDC in Atlanta, Georgia is one of the World Health Organization’s collaboration centers, in the 
United States the Food and Drug Administration makes the final decision on which vaccine 
viruses to include in the seasonal flu shot by February of each year (CDC, 2015). Even though 
the CDC does not make the final decision on the vaccine viruses, this organization is very 
important because they report information on influenza activity in the United States each week 
and conduct testing on the efficacy and ability of the seasonal flu shot to produce an immune 
response against the influenza virus (CDC, 2015). Another important part of the United States’ 
current influenza vaccination policy is the prioritization of target populations for the seasonal 
influenza vaccine. In general the CDC continues to recommend that everyone six months and 
older should get vaccinated against the influenza virus, but the CDC does recognize that there are 
certain high risks groups that are an even higher priority for vaccination. Some of these high 
risks groups include adults 65 and older, young children six months to five years old, and 
healthcare workers (Baguelin et al., 2013). As a result, many vaccination programs target these 
high risk groups especially during seasons where vaccine availability is limited. Also the people 
who are especially vulnerable to the influenza virus fall into high risks groups, and these high 
risk groups are determined based on who will suffer the worst health complications from getting 
the influenza virus. In the United States and other countries there is recognition that the influenza 
vaccine is not always perfect and that vaccination programs do have limitations and do need to 
be revamped from time to time. Therefore the CDC is very forthcoming with the limitations of 
the seasonal influenza vaccine. Such as there are multiple factors which limit the influenza 
vaccine and contributed to the vaccine’s efficacy which usually involve scientific issues and 
timing limitations. Although there are many different strains of the influenza virus, the influenza 
vaccine is limited by our scientific ability to be able to grow viable vaccine virus as vaccine 
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viruses can only be grown in pathogen-free chicken eggs or canine kidney cells (CDC, 2015). 
With these very specific criteria only certain vaccine viruses can be grown which means if a 
vaccine virus for a prevalent strain cannot be grown successfully then humans will have to 
remain unprotected. A large amount of a vaccine virus must be created in order for it to be 
included in the vaccine therefore time constraints sometimes limit which vaccines can be grown 
on time, and antigenic drift becomes a problem because even if antigenic drift is detected in 
some cases there just is not enough time to grown a vaccine virus that matches a variant strain 
which can be used in the vaccine (CDC, 2015). The importance of outlining the United States’ 
current influenza vaccination policy is to demonstrate how seriously this virus is taken from a 
public health standpoint and how much effort, time, research, and money is put into creating the 
best seasonal influenza vaccine possible. Although it is very true that much effort is put into 
creating an influenza vaccine each year there still is room for improvement which makes 
evaluating the efficacy of the influenza vaccine valuable as this can give insight into how 
changes in policy could continue to increase the influenza vaccine’s protective power which 
would benefit the humans population. 
With the vast amount of influenza virus surveillance and research that is conducted year-
round by many laboratories worldwide there are some key factors that have been identified 
which are proven to decrease the efficacy of the influenza vaccine. The singlehanded most 
important factor that decreases the efficacy of the influenza vaccine is the influenza virus’s 
ability to undergo antigenic drift. The influenza virus would be simple to track and vaccinate 
against if there was only one strain to target, but what makes the influenza virus so dangerous to 
public health is that fact that antigenic drift causes mutations in the genetic code of the virus 
which produces many different types of strains. Therefore when creating a vaccine for the 
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influenza virus each year it is comparable to trying to hit a moving target because antigenic drift 
allows the virus to change, and we can never be completely certain which strains will be most 
prevalent each year. To put the problem of antigenic drift into perspective, it has been found that 
antigenic drift is responsible for the global change in vaccine composition and since 1968 
antigenic drift had caused the influenza vaccine composition to be updated approximately every 
two to five years (Boni, 2008). Antigenic drift occurs as a means for the influenza virus to evade 
human immunity even in vaccinated individuals so clearly this ability can decrease the 
effectiveness of the influenza vaccine because the influenza virus is designed to change so that 
the human immune system cannot recognize the virus (Moldoveanu et al., 1999). Research on 
antigenic drift has provided information that suggests that antigenic drift occurs every two to 
eight years due to evolutionary pressure, and antigenic drift can occur in all strains of the A and 
B viruses (Kanai et al., 2010). On a biological level, changes to the genetic code of each viral 
strain due to antigenic drift are subtle usually only involving a point mutation of one nucleotide 
within antibody binding sites which occur at the hemagglutinin and neuraminidase viral proteins 
on the surface of the virus (Boni, 2008). As a result small changes to the virus can cause a 
significant impact on humans by causing an increased amount of illness and death by decreasing 
the efficacy of the influenza vaccine with the emergence of variant strains. Also antigenic drift 
causes varying evolutionary patterns as this type of biological change can causes the re-
emergence of old influenza strains or the creation of new variants (Boni, 2008). Overall it is 
proven that antigenic drift can decrease the efficacy of the influenza vaccine, but the impact 
varies between seasons based on when antigenic drift is most active. Next, vaccine strain 
mismatching is related to and a consequence of antigenic drift and this is a factor which is also 
known to decrease the efficacy of the influenza vaccine. In the United States production of the 
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seasonal influenza vaccine can take up to nine months, and due to this lengthy production period 
this gives the opportunity for antigenic drift to occur and a new prevalent strain of influenza can 
arise while the vaccine is still in production. The consequence of this is that if a new strain arises 
during this production period it would be too costly and there would not be enough time to 
include this new strain in the vaccine that is being produced. Therefore reduce effectiveness of 
the influenza vaccine and a potential for an epidemic can occur as one of the circulating strains 
will not match one of the vaccine strains making the human immune system vulnerable (CDC, 
2015). The last factor to be mentioned that decreased the efficacy of the influenza vaccine is herd 
immunity which occurs when the majority of the human population is vaccinated against the 
influenza virus. Herd immunity is significant because it is known that strong host immunity is 
the driving force that causes antigenic drift to occur in the influenza virus (Boni, 2008). 
Antigenic drift is triggered by strong herd immunity amongst a population because this causes 
the circulating influenza viruses to have low evolutionary fitness which in turn favors mutations 
to occur via antigenic drift. As a result mutations caused by antigenic drift increase the fitness of 
the influenza virus and allow the virus to escape the herd immunity and cause illness (Boni, 
2008). This relationship between herd immunity and antigenic drift means that increasing the 
number of vaccinated individuals in a population increases herd immunity which in turn 
increases antigenic drift. In terms of vaccination strategies, vaccinating too many people can 
actually have negative consequences in terms of influenza virus evolution whereas vaccinating 
fewer people or being more selective as to who should receive vaccination would increase 
influenza vaccine efficacy by decreasing antigenic drift (Boni, 2008). Although it seems that 
vaccinating fewer people would be advantageous this is an unrealistic solution to increase 
efficacy because there is also danger in vaccinating fewer people, therefore it would be better to 
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strengthen our influenza monitoring efforts during seasons where herd immunity is high in an 
effort to recognize sooner when antigenic drift occurs so the human population can be warned 
and take extra precautions. Typically in the United States the most vaccination for the influenza 
virus occurs in October and November which makes herd immunity high at the beginning of the 
flu season which in turn would make the emergence of variant influenza strains more likely to be 
recognizable by the end of the same flu season so more monitoring efforts during this time 
period would allow for earlier recognition of variant strains which could help improve the 
vaccine for next season (Boni, 2008). In order to tie this section together it is important to note 
that factors like vaccine strain mismatching and herd immunity are indirect factors that decrease 
the efficacy of the influenza vaccine as these factors are either a cause or consequence of 
antigenic drift which again is the main factor that decreases efficacy.  
 Within the scientific community concerned with the influenza vaccine and vaccination 
policy it is undebated that the efficacy of the influenza vaccine can be decreased, but what is 
debated is the best approaches to try to overcome the factors that can decrease the efficacy of the 
influenza vaccine. Formerly mentioned in this paper were three major factors that are widely 
known to negatively impact the efficacy of the influenza vaccine, and there are other less 
significant or newly discovered factors that have not been addressed. With so many factors that 
can possibly negatively impact the efficacy of the influenza vaccine there are many different 
suggested approaches that try to overcome these factors in an effort to ensure and increase the 
efficacy of the influenza vaccine. With so many laboratories and research worldwide dedicated 
to study the influenza virus and vaccine, there is a vast amount of data related to efficacy of the 
influenza vaccine that has to be sifted through and interpreted for future use. In this section of the 
paper I will cite some of the most common and widespread approaches that are being discussed 
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within the scientific community currently based off of available research that has been 
conducted. There is naturally a worldwide problem with decreased efficacy of the influenza 
vaccine as this would make the human population more vulnerable to illness, therefore looking 
into approaches that can maintain or increase the efficacy of the influenza vaccine is important 
because the main goal of the influenza vaccine and vaccination programs is to protect as many 
people from this virus as possible to decrease illness, death, and economic burden. As a result 
there seems to be two categories of approaches that are predominate within current scientific 
research, and these categories consist of either adapting vaccination policy and monitor efforts 
for the influenza virus or making improvements to the content of the vaccine itself. Both 
categories of approaches are valuable, and the first category of approaches to be discussed is 
ones that suggest making adaptations to vaccination policy and monitoring efforts. One 
suggested approach is to increase the use of sero-epidemiological testing which means to use 
serum from human blood to better understand the incidence and distribution of disease (Kanai et 
al., 2010). In the human immune response after receiving an influenza vaccine, the human body 
makes antibodies against the influenza virus therefore conducting research on serum and 
monitoring populations periodically could give better insight into how the body reacts to the 
influenza virus and vaccine on a biological level (Moldoveanu et al., 1999). It is important to 
note that the idea of conducting sero-epidemiological testing is not a new idea as mass 
serological surveys worldwide are already done each year to help determine which strains should 
be included in the vaccine, but what is new is the suggestion for better organizing and targeting 
how this testing should be conducted (Kanai et al., 2010). Although there is mass serological 
testing that is conducted each year a noticeable trend is that there is not much of this type of 
testing conducted in tropical regions such as in Southeast Asian countries. Therefore it may be 
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advantageous to the efficacy of the influenza vaccine and monitoring efforts if sero-
epidemiological is better allocated worldwide as the importance of this type of testing has been 
confirmed by its mass usage annually (Kanai et al., 2010). The suggestion of better allocating 
sero-epidemiological testing also alludes to the next approach to be discussed which is related to 
geography. Such as it is well known that different parts of the world play different roles in 
influenza virus evolution, therefore it is suggested that geographic considerations should be used 
to better target and monitor the emergence of novel strains of influenza and the stains that are 
most prevalent each year (Boni, 2008). Currently vaccine recommendations and strain 
monitoring are done on a global scale, but increasing monitoring on a smaller more localized 
scale can help indicate the regions that impact influenza virus evolution the most and target 
regions where the most antigenic drift occurs (Boni, 2008). Also climate plays an important role 
in peak influenza season and influenza virus evolution as influenza virus infection occurs 
throughout the year in tropical regions whereas in temperate regions infection most occurs in the 
winter season which is just one example of how geography can affect the influenza virus (Kanai 
et al., 2010). One geographic consideration that is known and valued is that it is important to 
have close monitoring for novel influenza variants in China and Southeast Asia, and this displays 
how if more attention is paid to geographic considerations there is the possibility that influenza 
monitoring can become more pointed and effective (Kanai et al., 2010). Another adaptation that 
is worth mentioning in terms of modification to influenza vaccination policy is the consideration 
to adjust target populations for influenza vaccination. Although the CDC recommends that 
everyone six months and older should get vaccinated against influenza, many vaccination 
programs target high risks groups like adults aged sixty-five and older or small children 
especially when vaccine availability is limited. Targeting these high risks groups is beneficial 
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because it offers protection to these groups by lowering the amount of illnesses and financial 
burden, but targeting other groups of people may offer a broader range of protection. Such as, 
children that are not young enough to be in the high risk category have been found to be the key 
spreaders of the influenza therefore it could be more beneficial to target children not in the high 
risk categories and the adults these children come in contact with in an effort to decrease the 
spread of the influenza virus in the first place (Baguelin et al., 2013). Specifically it has been 
found that the most optimal allocation of influenza vaccine would be to prioritize schoolchildren 
and adults aged thirty to thirty-nine as children are the key spreaders of the influenza virus and 
parents serve as a bridge to the rest of the population (Medlock & Galvani, 2009). Overall 
changes to vaccination policy and monitoring efforts are probably the fastest and most efficient 
routes to take in an effort to increase or maintain the efficacy of the influenza vaccine as changes 
to the vaccine itself would require lengthy clinical trials and testing.  
 Now that approaches pertaining to vaccination policy and monitoring efforts have been 
addressed, the next to be addressed are approaches pertaining to actual changes to the influenza 
vaccine itself in an effort to increase or maintain the efficacy of the influenza vaccine. Again, the 
approaches that will be discussed are the most current and prevalent in scientific research.  In the 
United States all seasonal influenza vaccines either contain three or four strains that are picked to 
be included in each dose of the vaccine, but one approach to increasing or maintaining the 
efficacy of the influenza vaccine is to add more strains to the vaccine. Adding more strains to the 
vaccine would allow humans to be protected against a broader range of strains, but this approach 
also has some disadvantages to it. Such as, adding more strains to the influenza vaccine could 
make the vaccine too costly or make the production process too long. Also adding more strains 
still would not guarantee that humans would be more protected if antigenic drift occurred. 
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Although this approach is not perfect or foolproof, it relates to the idea behind the second 
approach to be addressed which is cross protective vaccines. The idea behind cross protective 
vaccines is the same as adding more strains to the influenza vaccine which is that cross 
protective vaccines could reduce the impact of antigenic drift by helping the body make more 
antibodies that can possibly protect the immune system against a broader range of influenza 
strains and variant strains (Carrat & Flahault, 2007). Therefore cross protective vaccines could 
provide more protection against the influenza virus than the regular seasonal influenza vaccine 
could provide as cross protection can evoke an immune response that provides sufficient 
protection against some strains even if the vaccine components are not optimally matched which 
would be valuable to use during seasons where antigenic drift occurs (Heckler et al., 2006). 
Humans can gain cross reactive antibodies from the seasonal influenza shot when variant strains 
are somewhat similar to the strains included in the vaccine, but most importantly specific cross 
protective vaccines could be made as a supplement and provide more protection during seasons 
when a substantial amount of antigenic drift occurs and efficacy of the seasonal influenza 
vaccine is lowered (Katz et al., 2009). The last approach to be addressed is the proposal for a 
universal influenza vaccine which would completely change vaccination policy and eliminate the 
need for a constantly changing seasonal influenza vaccine. Research is now moving in this 
direction in search of a universal influenza vaccine because it would eliminate the problem of 
antigenic drift, but currently a universal vaccine for the influenza virus remains in a preclinical 
stage as much more research needs to be done (Carrat & Flahault, 2007). Hemagglutinin and 
Neuraminidase are viral proteins on the surface of the virus which are the most antigenic 
proteins, and the current seasonal influenza vaccine is based off of these proteins even though 
Hemagglutinin and Neuraminidase are highly susceptible to antigenic drift (Carrat & Flahault, 
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2007). Therefore the goal of  universal vaccine would to make a vaccine based on more 
conserved parts of the virus that are not heavily affected by antigenic drift so that the vaccine 
would remain effective and not be negatively impacted by variant strains (Carrat & Flahault, 
2007). Currently there has been research conducted on a part of the influenza virus called the M2 
ion channel protein which is a more conserved part of the virus, and ultimately targeting proteins 
like this would provide for protection across all strains of the influenza virus so there would be 
no need to worry about decreased efficacy of the vaccine (Carrat & Flahault, 2007). In general a 
lot more research needs to be conducted on improvement to the influenza vaccine itself, but 
some of these approaches may have a promising future if research advances to a point where 
these approaches are useable in creating an improved influenza vaccine for the human 
population.  
 Many approaches that are suggested to increase or maintain the efficacy of the influenza 
vaccine seem like valuable ideas which lead to the question as to why there is a gap between 
actual influenza vaccination policy and scientific evidence. Besides the fact that new approaches 
take time implement once they are deemed appropriate to use, there are multiple reasons why 
there is a gap between vaccination policy and scientific evidence. One reason which contributes 
to this gap is that many research studies only report data from one or two flu seasons which make 
the data produced from these types of studies unreliable and difficult to interpret because the 
circulation and incidence of the influenza virus varies greatly each year due to factors like 
antigenic drift (Jefferson, 2006). Another factor that contributes to this gap is based on the scale 
of each scientific study as studies with small numbers of participants or small data sets again 
make the data produced unreliable due to the limited scope of the study (Jefferson, 2006). 
Amongst other symptoms influenza is characterized as causing respiratory illness, and since 
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there are many other illnesses that cause similar symptoms it is almost impossible to differentiate 
actual influenza and influenza-like illness which in most cases is just considered to be influenza 
when it really is not (Jefferson, 2006). The confusion between influenza and influenza-like 
illness becomes problematic because it leads to an overestimation of the impact of influenza and 
unrealistic expectations of the success of influenza vaccines which can be reflected in evidence 
from scientific research as well (Jefferson, 2006). Besides these factors the integrity of the 
studies that report scientific evidence must be thoroughly scrutinized as many studies are poorly 
designed or biased which leads to confounders and inaccurate data that could never be used to 
help determine or modify vaccination policy (Jefferson, 2006). Overall the gap between 
vaccination policy and scientific evidence is justified because it is a lengthy process to extract 
scientific evidence produced by researchers that has merit and is reliable enough to include in 
vaccination policy. There may be pressure or temptation to use scientific evidence because it 
sounds good or seems like a viable way to deal with the influenza problem, but policy makers 
have to be very careful with which evidence they use because it would be a waste of resources 
like time and money to use them on improper evaluation (Miller et al., 2009). Lastly, immediate 
action always has to be taken against influenza in order to control this virus and hopefully there 
can be closer collaborations and lessons drawn from previous knowledge so that policy makers 
and researchers can possibly decrease the gap between policy and scientific evidence so that the 
human population can benefit from the outcome (Miller et al., 2009).  
 The influenza virus is nondiscriminatory and is a worldwide public health problem 
especially when pandemics and epidemics occur. Also the subject of the influenza virus is 
complicated because there are so many factors and collaborations that occur in an attempt to 
control this virus from causing illness and death. Hopefully this paper clarifies all the elements 
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that go into the public health intervention against the influenza virus, and above all indicates the 
need for continuous adaptation of both policy and vaccine composition in order to combat a 
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